



## **Scientific Committee on Consumer Safety (SCCS)**

### **WG on Methodologies**

**Venue: Luxembourg**

**Meeting date: 28 March 2014**

#### **Minutes**

#### **1. WELCOME AND APOLOGIES**

The Chair welcomed the participants. There was no apology.  
Cosmetics Europe (CoE) was invited to participate to the dedicated morning session.

#### **2. ADOPTION OF THE AGENDA**

The agenda was adopted as presented.

#### **3. DECLARATION OF INTEREST ON MATTERS ON THE AGENDA**

No declaration of potential conflict of interest was made.

#### **4. LOW BIOAVAILABILITY PRESENTATIONS**

- Introduction by the Chair: How to deal with low dermal absorption (DA) of cosmetic ingredients?
- Ursula Gundert-Remy: Toxicokinetic aspects of low dermal bioavailability
- Judith Madden: In silico tools for predicting ADME properties relevant to cosmetics: Interim report of activities in the COSMOS project
- Dagmar Bury, CoE: Low dermal bioavailability in practice: Compilation/examples of substances and analytical arguments for a cut-off value
- Vera Rogiers: The SCCS Database: retrospective analysis of the dermal absorption values obtained for ANNEX substances with focus on low bioavailability
- General discussion, conclusions, next steps and further follow-up took place

#### **5. INTERNAL MEETING OF THE WG METHODOLOGIES**

- Feedback from the morning meeting on low bioavailability
- BMD approach: introduction from the Chair and examples from SCCS members
- Bernard Bottex, EFSA: Use of the Benchmark Dose approach in Risk Assessment by EFSA Panels
- Discussion on the BMD approach

#### **6. ANY OTHER BUSINESS**

Next meeting is planned for 21 May 2014

**Attendance list of participants from Cosmetics Europe:**

- Dr Patric Amcoff, Interim Director Science & Research, Cosmetic Europe
- Dr Judith GIERNOTH, Cosmetic Europe
- Dr Dagmar BURY, Cosmetic Europe